Endoscopic Ultrasound Needles Market to Reach USD 0.58 Billion by 2036, Driven by Rising Cancer Diagnostics and Minimally Invasive Procedures - TMR

The global Endoscopic Ultrasound Needles Market is entering a period of strong expansion as healthcare providers increasingly adopt minimally invasive techniques for diagnosing and managing gastrointestinal, pancreatic, biliary, and related diseases. The market was valued at approximately USD 0.26 billion in 2025 and is projected to reach USD 0.58 billion by 2036, representing a CAGR of 8.3% from 2026 to 2036. Growing demand for accurate tissue sampling, increasing incidence of gastrointestinal and pancreatic cancers, and technological advancements in fine needle aspiration and biopsy devices are expected to remain central to market development.

Gain an understanding of key findings from our Report in this sample -

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=36161 

Market Overview

Endoscopic ultrasound needles are specialized devices used with endoscopic ultrasound systems to obtain tissue or fluid samples from lesions and structures located within or adjacent to the gastrointestinal tract. These needles support procedures such as tissue sampling, aspiration, biopsy, and diagnostic intervention, enabling physicians to access areas that can be difficult to reach using conventional biopsy approaches. EUS-guided procedures are particularly relevant to the diagnosis and staging of pancreatic lesions, gastrointestinal tumors, lymph nodes, liver lesions, and other abnormalities.

The growing emphasis on early diagnosis and precision medicine is increasing the clinical importance of EUS-guided sampling. Improvements in needle design, flexibility, echogenicity, penetration, and tissue acquisition are helping physicians obtain higher-quality specimens for cytological, histological, molecular, and biomarker analysis. Rising investment in advanced endoscopy facilities and growing acceptance of minimally invasive diagnostic techniques are further supporting market expansion.

Key Market Growth Drivers

The rising global burden of gastrointestinal and pancreatic diseases represents a major growth driver for the endoscopic ultrasound needles industry. Accurate diagnosis is critical for determining disease severity and selecting appropriate treatment, particularly in oncology. EUS-FNA and EUS-FNB procedures enable clinicians to obtain samples from hard-to-access lesions under real-time ultrasound guidance, reducing the need for more invasive diagnostic approaches.

The increasing prevalence of gastrointestinal cancers is strengthening demand for reliable biopsy technologies. Pancreatic lesions, gastrointestinal tumors, bile duct abnormalities, and suspicious lymph nodes frequently require tissue confirmation before treatment decisions are made. As healthcare systems place greater emphasis on early detection and accurate disease staging, demand for advanced EUS needles is expected to increase.

The growing preference for minimally invasive tissue sampling is another significant factor. EUS-guided procedures can provide access to deep lesions while generally reducing patient discomfort and recovery requirements compared with more invasive surgical approaches. Improvements in needle-tip configurations, stylet control, flexibility, echogenicity, and tissue capture are further enhancing procedural efficiency and supporting adoption among gastroenterologists and other specialists.

Analysis of Key Players and Key Player Strategies

The global market includes several established medical device manufacturers competing through product innovation, regulatory approvals, strategic collaborations, geographic expansion, and investments in research and development. Prominent companies include Olympus Corporation, Medtronic plc, Cook Medical LLC, Boston Scientific Corporation, CONMED Corporation, Medi-Globe GmbH, Micro-Tech Endoscopy, STERIS plc, ENDO-FLEX GmbH, and MTW Endoskopie Manufaktur W. Haag KG.

These companies are focusing on developing next-generation FNA and FNB needles capable of delivering improved tissue acquisition and greater procedural control. Manufacturers are also emphasizing compatibility with contemporary echoendoscopy systems and the ability to obtain specimens suitable for increasingly sophisticated pathological and molecular testing.

Regulatory clearances and new product introductions are supporting competition. In January 2026, Olympus Corporation of the Americas announced the U.S. launch of its SecureFlex™ Single-Use Fine Needle Biopsy Device. The device is designed for ultrasound-guided tissue sampling and is available in 19G, 22G, and 25G configurations. Such developments demonstrate the industry's emphasis on single-use technologies and improved tissue collection for difficult-to-reach lesions.

Access detailed insights by visiting our full report -

https://www.transparencymarketresearch.com/endoscopic-ultrasound-needles-market.html 

Market Challenges and Opportunities

Despite favorable growth prospects, the market faces challenges associated with the cost of advanced endoscopy equipment, the requirement for skilled professionals, procedural complexity, and regulatory requirements governing medical devices. The successful performance of EUS-guided biopsy also depends on physician expertise, appropriate imaging equipment, and access to pathology services. These factors can restrict adoption in healthcare systems with limited infrastructure or trained specialists.

At the same time, the growing integration of EUS-guided biopsy with precision oncology presents significant opportunities. Modern cancer treatment increasingly depends on detailed pathological and molecular information, creating demand for tissue samples of sufficient quality and quantity for advanced testing. Manufacturers that develop needles capable of producing larger, better-preserved specimens while minimizing the need for repeat procedures could gain a competitive advantage.

Key Player Strategies

Leading market participants are pursuing product differentiation through advanced needle-tip designs, enhanced echogenicity, greater flexibility, and improved tissue acquisition capabilities. Companies are also expanding disposable product portfolios to support infection-control requirements and procedural convenience. Regulatory approvals in major markets remain an important strategy for strengthening product adoption and expanding commercial reach.

Strategic partnerships, investments in research and development, physician training, and broader distribution networks are also shaping the competitive landscape. Companies are increasingly targeting oncology and gastroenterology centers where demand for EUS-guided diagnostic procedures is particularly strong. Continued innovation is expected to focus on improving sampling efficiency while supporting compatibility with emerging imaging and diagnostic platforms.Investment Landscape and ROI Outlook

The endoscopic ultrasound needles market offers attractive long-term investment prospects due to its connection with expanding cancer diagnostics, minimally invasive medicine, and precision healthcare. The projected increase from USD 0.26 billion in 2025 to USD 0.58 billion in 2036 indicates considerable room for manufacturers and technology providers to expand their presence.

Investment opportunities are particularly promising in advanced FNB technologies, single-use devices, and products designed for molecular and biomarker testing. Companies capable of increasing diagnostic yield while reducing repeat biopsies may generate stronger value for hospitals and physicians. Expansion of endoscopy infrastructure in emerging markets also creates opportunities for suppliers seeking to establish early positions in developing healthcare systems.

Market Segmentation and Regional Outlook

The endoscopic ultrasound needles market is segmented by product into Fine Needle Aspiration (FNA) Needles, or EUS-FNA, and Fine Needle Biopsy (FNB) Needles, or EUS-FNB. By application, the market covers bronchial and enteral procedures, while end users include hospitals, specialty clinics, and ambulatory surgery centers. Geographically, the market encompasses North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America led the global market in 2025, accounting for approximately 40% of revenue. The region benefits from advanced healthcare infrastructure, high adoption of EUS-guided procedures, a strong base of gastroenterology and oncology specialists, and substantial investment in advanced diagnostic technologies. The high incidence of gastrointestinal and pancreatic cancers also supports demand for tissue sampling devices.

By product, EUS-FNA held the leading position in 2025, accounting for approximately 61% of market revenue. Its widespread use in pancreatic, gastrointestinal, biliary, and mediastinal disease diagnosis continues to support its dominance. However, FNB technologies are expected to gain increasing attention as clinicians seek larger and more suitable tissue specimens for histological and molecular analysis.

Why Buy This Report?

The Endoscopic Ultrasound Needles Market report provides stakeholders with a comprehensive assessment of market size, growth trends, competitive dynamics, emerging opportunities, technological developments, and regional prospects through 2036. The study combines quantitative forecasts with qualitative analysis covering market drivers, restraints, opportunities, value-chain developments, key trends, and the competitive landscape. It can help medical device manufacturers, investors, healthcare providers, distributors, and other industry participants identify high-growth opportunities, evaluate regional markets, understand competitor strategies, and support informed business and investment decisions.

Frequently Asked Questions

What is the projected size of the Endoscopic Ultrasound Needles Market by 2036? The global market is projected to reach approximately USD 0.58 billion by 2036, compared with USD 0.26 billion in 2025.

What is the expected CAGR of the market? The market is forecast to expand at a CAGR of 8.3% from 2026 to 2036, supported by growing demand for minimally invasive tissue sampling and cancer diagnostics.

Which region currently dominates the market? North America is the leading regional market, accounting for approximately 40% of global revenue in 2025, supported by advanced healthcare infrastructure and widespread adoption of EUS-guided procedures.

Which product segment holds the largest market share? The EUS-FNA segment leads the market, accounting for approximately 61% of revenue in 2025, owing to its extensive application in diagnosing gastrointestinal, pancreatic, biliary, and mediastinal diseases.

What are the major opportunities in the market? The expansion of EUS-guided biopsy in precision oncology represents a significant opportunity. Increasing demand for high-quality tissue samples for histological, molecular, and biomarker testing is expected to encourage further innovation in FNA and FNB needle technologies.

Buy this Premium Research Report and access vital insights and analysis -

https://www.transparencymarketresearch.com/checkout.php?rep_id=36161<ype=S 

More Trending Reports by Transparency Market Research -

Anti-Acne Dermal Patch Market

GCC Countries Vertical Lift Module Market

Folding Cartons Market

Influenza Vaccine Market

Computed Tomography (CT) Market

U.S. Nicotine Pouches Market

Cancer Biomarkers Market

Acetylene Market

Sleep Apnea Devices Market

Digital Signage Market

Skin Care Market

Autoinjectors Market

Activated Carbon Market

Propane Market

Neodymium Market

Atomic Force Microscopes (AFM) Market

Lithium-ion Battery Market

Fencing Market

Ceramic Sanitary Ware Market

Base Oil Market

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact:

Abhishek Budholiya

Transparency Market Research Inc.

State Tower, 90 State Street, Suite 700,

Albany NY - 12207, United States

Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com 

Sales Inquiries: sales@transparencymarketresearch.com 

Media Inquiries: media@transparencymarketresearch.com